Highest-materiality recent filing
Omnicell appoints Nnamdi Njoku as President; Lipps remains CEO and Chairman
Nnamdi Njoku appointed President of Omnicell effective July 1, 2026, while retaining COO role.
Omnicell shareholders approve 1.6M share increase to equity plan and officer exculpation amendment
Stockholders approved amendment to 2009 Equity Incentive Plan adding 1,600,000 shares (35.2M for, 1.5M against).
Omnicell Q1 revenue $310M (+15% YoY); raises FY2026 non-GAAP EBITDA/EPS guidance
GAAP net income $11M ($0.25/diluted) vs loss of $7M ($0.15 loss) in Q1 2025.
Omnicell Q4 rev $314M (+2% YoY), GAAP net loss $0.05/sh; FY26 revenue guide $1.215-1.255B
Q4 total revenues $314M (+2% YoY); full-year 2025 rev $1.185B (+7% YoY).
Omnicell launches Titan XT automated dispensing system powered by OmniSphere cloud platform
Launch of Omnicell Titan XT, a next-gen automated dispensing system for autonomous medication management, available now in US.
Omnicell Q3 rev $311M (+10% YoY), beats guidance; raises FY2025 outlook
Q3 revenue $311M (+10% YoY); GAAP EPS $0.12, non-GAAP EPS $0.51; non-GAAP EBITDA $41M.
Omnicell adopts amended bylaws with enhanced stockholder nomination and proposal procedures
Board adopted fourth amended and restated bylaws effective September 30, 2025.
Omnicell appoints Baird Radford as CFO effective Aug 26; Etta steps down
Baird Radford appointed EVP and CFO effective August 26, 2025; succeeds Nchacha Etta who steps down.
Omnicell Q2 2025 revenue $291M (+5% YoY), beats guidance; raises FY2025 outlook
Total revenues $291M (+5% YoY); GAAP EPS $0.12, non-GAAP EPS $0.45.
CFO Nchacha Etta to depart; employment extended through Nov 15, 2025, or until successor appointed.
Omnicell stockholders approve 1.75M share increase to 2009 equity plan; re-elect directors
Stockholders elected Edward P. Bousa, Mary Garrett, and Bruce E. Scott as Class III directors for three-year terms.
Omnicell raises Q2 and FY2025 profit outlook on tariff relief; authorizes $75M share buyback
Q2 Non-GAAP EBITDA guidance raised to $25-31M (from $22-30M); Non-GAAP EPS raised to $0.24-0.34 (from $0.19-0.32).
Omnicell Q1 revenue $270M (+10% YoY); non-GAAP EPS $0.26 vs $0.03; FY guidance cut
Total revenues $270M, up 10% YoY; GAAP net loss $7M ($0.15) vs loss $16M ($0.34) YoY.
Omnicell CFO Nchacha Etta to step down by Sept 2025; company reiterates 2025 guidance
Nchacha Etta steps down as EVP & CFO effective Sept 15, 2025 or upon successor appointment; national search underway.
Omnicell enters new CEO employment agreement with Randall Lipps through Dec 2027
Base salary of at least $833,000; annual cash bonus target no less than 125% of base salary.
Omnicell Q4 revenue $307M (+19% YoY); 2025 guides ARR $610-630M, product bookings $500-550M
Q4 total revenues $307M, up 19% YoY; GAAP net income $16M ($0.34 diluted) vs loss of $14M in Q4 2023.
Omnicell issues $172.5M 1.00% convertible notes due 2029, repurchases $400M of 2025 notes
Priced $150M (upsized to $172.5M) of 1.00% Convertible Senior Notes due 2029; conversion price ~$57.25 (35% premium).
Omnicell proposes $150M convertible notes due 2029; to repurchase up to $400M of 2025 notes
Offers $150M aggregate principal of 0.25% Convertible Senior Notes due 2029, plus $22.5M greenshoe.
Omnicell Q3 revenue $282M (-5% YoY); raises FY2024 non-GAAP EBITDA & EPS guidance
Q3 GAAP net income $9M ($0.19/diluted) vs. $6M ($0.12) YoY; non-GAAP EPS $0.56 vs. $0.62.
Omnicell appoints Nnamdi Njoku as EVP and COO, effective Oct 7
Nnamdi Njoku named EVP and Chief Operating Officer; role reports to CEO Randall Lipps.
Omnicell Q2 revenue $277M, non-GAAP EPS $0.51; raises FY 2024 guidance
GAAP net income $4M ($0.08 diluted); non-GAAP net income $24M ($0.51 diluted).
Omnicell extends CAO Joseph Spears retirement to June 30, 2024
Spears originally set to retire May 31, 2024; new date is June 30, 2024.
Stockholders approved amendment to 2009 Equity Incentive Plan, adding 2,462,000 shares to authorized pool.
Omnicell Q1 revenues down 15% to $246M, GAAP net loss $0.34/sh; initiates wind-down of Medimat RDS
Q1 GAAP revenues $246M (-15% YoY); GAAP net loss $16M ($0.34/sh) vs loss $15M ($0.33/sh) last year.
Omnicell appoints Brian Nutt as Chief Accounting Officer; Joseph Spears to retire May 31, 2024
Joseph Spears to retire as SVP, Chief Accounting Officer effective May 31, 2024; will remain as executive adviser until then.
Omnicell FY2023 rev $1.147B (-11% YoY), GAAP net loss $0.45/sh; FY2024 guidance below prior year
FY2023 total revenue $1.147B, down 11% YoY; GAAP net loss $20M ($0.45/sh) vs prior year GAAP net income $6M.
Omnicell elects Eileen Voynick to Board; Sara White resigns; Vance Moore not standing for reelection
Sara White resigned as director effective Jan 5, 2024, for personal reasons; no disagreement with company.
Omnicell EVP & Chief Commercial Officer Seidelmann departs; $868K severance
Scott P. Seidelmann separated Nov 3, 2023; had transitioned to Special Adviser to CEO on June 1.
Omnicell Q3 rev $299M (-14% YoY); non-GAAP EPS $0.62; cuts FY23 guidance; plans 7% RIF
GAAP revenue $299M (-14% YoY); net income $6M ($0.12 diluted) vs $17M ($0.37) in Q3 2022.
Omnicell enters $350M revolver, down from $500M; includes incremental facility
Five-year revolving credit facility of $350M, downsized from $500M in prior agreement.
Omnicell extends Seidelmann's exit to Nov 3; Mellon gets $760K severance
Scott Seidelmann's separation as EVP & Chief Commercial Officer moved from Oct 1 to Nov 3, 2023; he remains an executive adviser.
Omnicell board rejects director Seim's resignation, removes him from audit committee
Seim received majority withheld votes at May 2023 annual meeting and submitted resignation.
Omnicell CFO Peter Kuipers terminated without cause; severance includes $898K lump sum
CFO Peter J. Kuipers terminated without cause effective Aug 1, 2023; separation agreement signed Aug 4.
Omnicell adopts new Executive Severance Plan with enhanced CIC benefits for named officers
Plan approved July 30, 2023, covers CEO, EVPs, and SVP (Nchacha Etta, Corey Manley, etc.)
Omnicell Q2 revenue $299M (-10% YoY); non-GAAP EPS $0.57 beats guidance; FY outlook $1.16-1.20B
GAAP revenue $299M (-10% YoY); GAAP EPS $0.08; non-GAAP EPS $0.57 (beat guidance).
Omnicell appoints Bobby Ghoshal to Board of Directors as independent director
Board expanded from 9 to 10; Ghoshal elected Class II director, term expiring at 2024 Annual Meeting.
Omnicell extends outgoing CFO Peter Kuipers' separation date to August 1, 2023
Separation date extended from July 1 to August 1, 2023.
Omnicell eliminates CCO and Chief Admin Officer roles; promotes several execs
Scott Seidelmann, EVP/Chief Commercial Officer, steps down effective June 1, 2023; role eliminated.
Omnicell stockholders approve 3M share addition to ESPP and 1.6M to equity plan
Elected three Class I directors: Joanne B. Bauer, Robin G. Seim, Sara J. White.
Omnicell appoints Nchacha E. Etta as CFO effective June 1, 2023; Kuipers departing July 1
Nchacha E. Etta appointed EVP and CFO, effective June 1, 2023, succeeding Peter Kuipers.
Omnicell Q1 2023 revenue down 9% YoY to $291M, GAAP net loss of $0.33 per share
Total GAAP revenues $291M (-9% YoY); GAAP net loss $15M ($0.33 loss per share) vs net income $8M ($0.17) prior year.
Omnicell amends credit agreement to replace LIBOR with SOFR benchmark
Second Amendment to $500M credit agreement replaces LIBOR with SOFR plus 0.10% credit spread adjustment.
Omnicell Q4 GAAP loss $0.64; FY2022 revenue up 14%; CFO to step down; cuts 60 jobs
Q4 GAAP net loss $28M ($0.64 loss per share) vs net income $14M ($0.28) in Q4 2021; FY2022 GAAP net income $6M ($0.12) vs $78M ($1.62) in 2021.
Omnicell to cut 9% of workforce (~350 employees) in restructuring plan
Plan approved Nov 23, 2022; reduces headcount by ~350 (9% of total workforce).
Omnicell Q3 revenue $348M (+17% YoY); GAAP EPS $0.37; guides Q4 revenue $285M-$295M
GAAP net income $17M ($0.37/diluted share) vs $29M ($0.61) in Q3 2021.
Omnicell adopts amended bylaws for universal proxy rules and DGCL updates
Enhanced procedural mechanics for stockholder nominations, including resignation obligations for nominees.
Omnicell holds Investor Day, discusses long-term financial targets and strategy
Investor Day held September 20, 2022; slides presented are furnished as Exhibit 99.1.
Omnicell unveils 2025 financial targets: $1.9-2.0B revenue, 23% EBITDA margin
Total revenue target of $1.9-$2.0B by 2025, representing 14-15% CAGR.
Omnicell Q2 revenue up 22% to $331M, non-GAAP EPS $0.84; reaffirms FY guidance; ransomware update
GAAP revenue $331M (+22% YoY); GAAP EPS $0.20 vs $0.43; non-GAAP EPS $0.84 vs $0.97.
Omnicell shareholders approve 1.1M additional shares under 2009 equity plan; directors elected
Shareholders approved amendment to 2009 Equity Incentive Plan authorizing 1,100,000 new shares (For: 35,598,967; Against: 3,678,452).
On March 12, 2025, Omnicell, Inc. (“Omnicell” or the “Company”) filed a Current Report on Form 8-K disclosing that Nchacha Etta would step down from his role as Executive Vice President, Chief Financial Officer of the Company, effective September 15, 2025 or until a successor is named.
On March 12, 2025, Omnicell, Inc. (the “Company”) announced that Nchacha Etta will step down from his role as Executive Vice President, Chief Financial Officer of the Company, effective September 15, 2025 or until a successor is named.
On September 25, 2024, Omnicell, Inc. (“Omnicell” or the “Company”) announced that Nnamdi Njoku, age 48, has been appointed Executive Vice President and Chief Operating Officer of the Company, effective October 7, 2024.
On February 23, 2024, Joseph B. Spears notified Omnicell, Inc. (the “Company” or “Omnicell”) that he will retire and depart from the Company, effective May 31 , 2024 (the “Spears Retirement Date”).
In addition, effective March 18, 2024, Omnicell has hired Brian Nutt, age 54, to serve as Vice President, Chief Accounting Officer, of the Company.
On January 5, 2024, Sara J. White resigned as a member of the board of directors (the “Board”) of Omnicell, Inc. (the “Company”), including from her position on the Corporate Governance Committee, effective as of January 5, 2024
On January 5, 2024, Vance B. Moore informed the Company that he will not stand for reelection as a Class II director at the 2024 Annual Meeting.
On January 5, 2024, the Board elected Eileen Voynick, effective immediately, to fill the vacancy created by Ms. White’s resignation and to serve as a Class I director with a term expiring at the 2026 annual meeting of stockholders.
Scott P. Seidelmann separated from the Company on November 3, 2023
Ms. Mellon separated from the Company on October 1, 2023
removed Mr. Seim as the Chair and a member of the Audit Committee;
As previously disclosed, Mr. Kuipers was terminated without cause from the Company on August 1, 2023
Max materiality 0.85 · Median 0.57 · Most common event leadership